Project Grant R01CA285580
Award Date
8/13/24
Completion Date
7/31/29
Dollars Obligated
$1.2M
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
미국 뉴욕
Similar Awards
The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395) to the Icahn School of Medicine at Mount Sinai (ISMMS) in the amount of $532,970. The grant, awarded on April 1, 2025, will support a 5-year research project aimed at defining the key cell-intrinsic features and cell interactions of anti-tumor CD4 T cells that promote anti-tumor immunity and enhance responses to PD-1 targeted immunotherapy. The research project will...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to the Icahn School of Medicine at Mount Sinai to conduct a multi-scale analysis of the Bacillus Calmette-Guerin (BCG) resistant tumor microenvironment in non-muscle invasive bladder cancer. The $684,877 award, with a project period from April 2025 to March 2030, will leverage single-cell and spatial sequencing techniques across 36 samples to elucidate the cellular, genomic, and...
The National Cancer Institute (NCI) awarded a $680,334 Project Grant under the Cancer Biology Research (CFDA 93.396) federal grant program to the Icahn School of Medicine at Mount Sinai (ISMMS). The 5-year grant, which began on March 1, 2025, aims to elucidate the specific molecular mechanisms and cellular players driving age-associated pro-tumoral myelopoiesis. The research will involve high-dimensional profiling of tumors from an early-stage lung cancer patient cohort, multi-omics...
This National Cancer Institute (CFDA 93.396 Cancer Biology Research) Project Grant award of $560,297 to the Icahn School of Medicine at Mount Sinai will fund research to functionally and molecularly characterize a potential second stem cell population, referred to as oncofetal stem cells (ONFSCs), in colorectal cancer (CRC). The overarching goal is to better understand the role of ONFSCs in driving tumor evolution and plasticity, with the aim of identifying novel therapeutic approaches....
This Project Grant award of $518,219 from the National Cancer Institute (NCI) under the Cancer Biology Research (CFDA 93.396) program supports research at the University of Pittsburgh to decipher the molecular mechanisms underlying cholangiocarcinoma (CCA) development. The 5-year project aims to investigate the intertwined roles of nuclear receptors FXR and CAR in promoting the malignant transformation of hepatocytes into CCA, particularly in the context of cholestatic liver diseases. The...
This $107,948 federal Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) supports research at the Icahn School of Medicine at Mount Sinai (ISMMS) to investigate the role of the interferon-gamma (IFNγ) signaling pathway in the tumor microenvironment and its impact on immune checkpoint blockade therapy for non-small cell lung cancer. The key objectives are to: 1) Explore how knockout of the SOCS1 gene, a negative regulator of the IFNγ pathway,...
The National Cancer Institute (NCI) awarded a $145,336 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Sloan-Kettering Institute for Cancer Research. The grant, with a performance period from March 1, 2025 to February 28, 2027, will support research to metabolically reprogram hepatic macrophages to overcome the "immune-desert" phenotype of B-catenin-driven hepatocellular carcinoma. The project aims to determine how TSC1-deficient hepatic macrophages can...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to Mayo Clinic to conduct a phase II clinical trial and accompanying mechanistic research on a novel combination immunotherapy approach for unresectable intrahepatic cholangiocarcinoma (ICCA), a rare and aggressive type of liver cancer. The key products and services to be delivered under this $610,890 award, with a project period from September 1, 2024 to August 31, 2029,...
This federal Project Grant award of $671,384 from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports research to develop new biomarkers for cholangiocarcinoma (CCA) based on changes in glycosylation patterns observed in CCA tissue and serum samples. The primary awardee, the Medical University of South Carolina (MUSC), will collaborate with sub-awardees Mayo Clinic and the University of Texas Southwestern Medical Center to...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) provides $196,029 to the University of Massachusetts Medical School (UMass Medical) to conduct research aimed at deciphering the immune evasion mechanisms associated with mutant isocitrate dehydrogenase 1 (mIDH1) in various solid tumors, including intrahepatic cholangiocarcinoma. The research focuses on two key objectives: 1) Elucidating the role of viral mimicry in the response to mIDH1...